When Is FDA Form 3988 Required? (w/Examples) + FAQs

FDA Form 3988 is required whenever a drug or biological product sponsor submits any postmarketing requirement (PMR) or postmarketing commitment (PMC)-related document to the FDA—except for the Annual Status Report. This form serves as a transmittal sheet that accompanies protocols, interim reports, final reports, and other correspondence tied to studies the FDA either mandates or that sponsors agree to conduct after a drug wins approval.

Under 21 CFR 314.81(b)(2)(vii) and 601.70, drug companies must conduct and report on postmarketing studies that evaluate a product’s clinical safety, clinical efficacy, clinical pharmacology, or nonclinical toxicology. Failure to comply with these requirements can result in civil monetary penalties of up to $250,000 per violation, plus additional daily fines if the violation continues. The FDA can also declare your product misbranded under Section 502(z) of the FD&C Act—a status that effectively makes it illegal to sell.

Here is what makes this topic critical: according to FDA’s FY 2022 annual report, approximately 30% of all required postmarketing studies were off-schedule for completion. Only half of PMRs established in FY 2016 had been fulfilled six years later.

In this article, you will learn:

📋 What FDA Form 3988 is and when it must accompany your submissions

⚖️ The difference between postmarketing requirements (PMRs) and postmarketing commitments (PMCs)—and why the distinction affects your legal exposure

📝 How to complete each field on Form 3988 correctly to avoid routing delays and compliance issues

🚨 The consequences of missing milestones, including warning letters and civil monetary penalties

✅ Step-by-step scenarios with action-consequence tables showing exactly when and how to use this form

What Are Postmarketing Requirements and Postmarketing Commitments?

Before understanding when Form 3988 is required, you must first understand the two types of studies it covers. The FDA divides postapproval studies into two categories: postmarketing requirements (PMRs) and postmarketing commitments (PMCs).

Postmarketing Requirements (PMRs)

A PMR is a study or clinical trial that the FDA legally requires a sponsor to conduct after approval. The FDA can mandate PMRs under several statutes and regulations. These include section 505(o)(3) of the FD&C Act (for safety studies), the Pediatric Research Equity Act (PREA), the accelerated approval pathway, and the Animal Efficacy Rule.

A PMR is not optional. If you fail to conduct the study according to the agreed-upon timetable, the FDA considers you in violation of federal law. This violation triggers enforcement consequences discussed later in this article.

Postmarketing Commitments (PMCs)

A PMC is a study that a sponsor voluntarily agrees to conduct but is not required by statute or regulation. Before 2008, nearly 90% of all postmarketing studies were voluntary commitments. The FDA Amendments Act of 2007 (FDAAA) changed this by giving the FDA expanded authority to require studies under section 505(o)(3).

While PMCs are voluntary, they are not consequence-free. Once you agree in writing to conduct a PMC, you must report annually on its status. The FDA tracks PMC performance and publishes this information publicly in its Postmarketing Requirements and Commitments database.

When Is FDA Form 3988 Required?

Form 3988 must accompany every PMR/PMC-related submission you send to the FDA—with one exception: the Annual Status Report (ASR). The ASR uses a different form (FDA Form 3989) and follows different submission rules.

According to FDA’s September 2023 guidance, Form 3988 should accompany PMR/PMC-related submissions for New Drug Applications (NDAs), Biologics License Applications (BLAs), Abbreviated New Drug Applications (ANDAs), and Investigational New Drug (IND) applications.

Specific Submissions That Require Form 3988

The following submission types must include Form 3988:

Draft Protocols – When you submit a proposed study design for FDA review before finalizing it. Clinical protocols go to your IND with a cross-reference letter to the marketing application.

Final Protocols – The version you intend to execute. Note: The FDA will not consider a protocol “final” until it has reviewed and fully agreed with your submitted protocol.

Interim Reports – Progress reports submitted during the study, often required annually as PMR/PMC milestones.

Final Reports – The summary report you submit when a study is complete. The FDA reviews this to determine if the requirement or commitment has been fulfilled.

General Correspondence – Questions about study design, updates on progress, or other communications that do not fit the other categories.

PREA PMR Deferral Extension Requests – Requests to extend the due date for pediatric studies required under the Pediatric Research Equity Act.

Responses to Information Requests – Replies to FDA requests for additional information about a PMR or PMC.

Requests for Revised Milestones – When you need to change your original submission dates for protocols, study completion, or final reports.

Requests for Release from PMR/PMC – When you believe the study is no longer feasible or would no longer provide useful information.

When Form 3988 Is NOT Required

Do not include Form 3988 with the following:

• Annual Status Reports (ASRs) – Use Form 3989 instead
• Cross-reference letters – If you submit a protocol to your IND and send a cross-reference letter to the marketing application, the cross-reference letter does not need Form 3988
• Chemistry, Manufacturing, and Controls (CMC) commitments – These are not subject to section 506B reporting requirements
• Voluntary studies – Studies not required by FDA and not agreed upon in writing are not tracked under 506B

How to Complete FDA Form 3988: Field-by-Field Instructions

Form 3988 contains 17 fields plus additional sections for PMR/PMC information. Completing each field accurately ensures your submission routes correctly to the right FDA reviewer. Errors can cause delays and compliance headaches.

Field 1: Center

Check only one box indicating which FDA center approved or licensed your application. Your options are CDER (Center for Drug Evaluation and Research) or CBER (Center for Biologics Evaluation and Research).

Why this matters: Selecting the wrong center can send your submission to the wrong review team, causing delays that may affect your milestone compliance.

Field 2: Date of Submission

Enter the date you are submitting this form to the FDA. Use the mm/dd/yyyy format. The date must match the date on your cover letter.

Field 3: Applicant Name

Enter your company name. For NDAs and ANDAs, the applicant is the person or legal entity that submitted the application. For BLAs, the applicant is the entity to whom the license was issued.

Field 4: Application Type

Select only one application type: NDA, BLA, ANDA, or IND. If your PMR/PMC relates to a protocol submitted to an IND that supports a marketing application, select IND.

Field 5: Application Number

Provide the six-digit application number. If your number is fewer than six digits, add leading zeros. For example, NDA 12345 becomes 012345. For BLAs, enter the six-digit application number/Submission Tracking Number (STN).

Field 6: Supplement Number(s)

For CDER-managed applications, provide the four-digit supplement number(s) where the PMR/PMC was established. Precede numbers fewer than four digits with zeros. If multiple supplement numbers apply, separate them with commas.

Field 7: Established Name

Provide the established name (USP or USAN name) for the approved drug product. For biological products, provide the proper name.

Field 8: Proprietary Name(s)

Enter the trade name, if the product has one.

Section 9: PMR/PMC Information

This section captures details about each PMR or PMC addressed in your submission. If your submission covers more than three PMRs/PMCs, use the “Add Row” button to add additional entries.

Field 10: PMR/PMC Submission Type

Check all document types you are submitting with this form. Options include Draft Protocol, Final Protocol, Interim Report, Final Report, General Correspondence, PREA PMR Deferral Extension Request, Response to Information Request, Request for Revised Milestones, Request for Release of PMR/PMC, and Other.

For requests involving missed 505(o)(3) PMR milestones, your cover letter must include the heading: “Notification of Failure to Meet a PMR Milestone(s) Required Under Section 505(o)” or “Notification of Anticipated Failure to Meet a PMR Milestone(s) Required Under Section 505(o).”

Field 11: Description of Submission Content

Provide a brief explanation of what you are submitting and why. Examples from FDA’s instructions include:

• “to provide the final protocol for PMR [number] incorporating information from our recent communications with FDA”
• “to provide the final report to fulfill PMR [number]”
• “general correspondence requesting a release from PMR [number] because…”

Fields 12-16: Responsible Official Information

Enter the name, title, date, telephone number, fax number, email address, and address of your company’s Responsible Official. This person certifies compliance with applicable laws and regulations.

Foreign applicants: If the person signing the form does not reside or have a place of business in the U.S., the form must be countersigned by an authorized U.S. agent in Field 17.b.

Field 17: Signatures

Field 17.a. requires the signature of the applicant or the applicant’s authorized official. Field 17.b. requires a countersignature from an authorized U.S. agent if the signer in 17.a. is located outside the U.S.

How to Submit Form 3988

FDA Form 3988 must be submitted electronically. Under section 745A(a) of the FD&C Act, certain human pharmaceutical product applications and related submissions must use the electronic Common Technical Document (eCTD) format.

Placement in the eCTD

According to FDA guidance, Form 3988 should be submitted in section 1.1, Forms, in the eCTD. If your eCTD publishing tool does not have a place for Form 3988 under section 1.1, submit it to section 1.2, Cover Letter.

Electronic Signatures

Form 3988 is a fillable PDF that supports electronic signatures. Once all required fields are completed, click the “Sign” button on the right side of Field 17.a. to open the electronic signature field.

Relationship to Other Forms

Form 3988 does not replace Form FDA 356h (Application to Market a New or Abbreviated New Drug or Biologic for Human Use). You must still submit Form 356h with your original and supplemental NDAs, ANDAs, and BLAs as applicable.

Form 3988 vs. Form 3989: Understanding the Difference

Many regulatory professionals confuse these two forms. The distinction is simple but critical:

Form 3989 replaces the content you would otherwise include in eCTD section 1.13.12 (Status of Postmarketing Commitments and Requirements). You should submit either a company-derived Annual Status Report or a completed Form 3989—not both.

When submitting Form 3989, you must also complete and submit Form FDA 2252 (Transmittal of Annual Reports for Drugs and Biologics for Human Use). For NDAs, reference Form 3989 in section 9.g. of Form 2252. For BLAs, check the box in section 10.a.

Real-World Scenarios: When Form 3988 Is Needed

Understanding when to use Form 3988 becomes clearer through practical scenarios. Below are three common situations drug sponsors face.

Scenario 1: Submitting a Final Protocol for an Accelerated Approval PMR

Background: Your oncology drug received accelerated approval based on tumor response rate as a surrogate endpoint. The FDA required you to conduct a confirmatory trial to verify clinical benefit. You have completed protocol development and are ready to submit the final protocol.

Key point: Even though you select “Final Protocol” in Field 10, the FDA will not consider the protocol final until they review and fully concur with it.

Scenario 2: Requesting Release from a PMC That Is No Longer Feasible

Background: Your company agreed to conduct a postmarketing observational study as a PMC. Since the agreement, new safety data from post-market surveillance has answered the questions the study was designed to address. You believe the PMC is no longer necessary.

Key point: A PMC release is not automatic. You must continue all reporting obligations until the FDA provides written notification that the PMC has been released.

Scenario 3: Missing a PMR Milestone and Requesting Revised Dates

Background: Your pediatric safety study required under PREA has experienced enrollment delays. The original final report submission date is approaching, and you will not meet it.

Key point: For PMRs under section 505(o)(3), you must notify the FDA if you anticipate missing or have missed a milestone. The FDA will determine whether you have “good cause” for the delay. Without good cause, enforcement consequences apply.

Mistakes to Avoid When Using Form 3988

Regulatory professionals commonly make several errors when completing and submitting Form 3988. Each mistake can lead to delays, compliance issues, or enforcement actions.

Mistake 1: Submitting Form 3988 with the Annual Status Report

What happens: The Annual Status Report should use Form 3989, not Form 3988. Including Form 3988 with your ASR creates confusion and may delay processing.

How to avoid it: Remember the rule: Form 3988 is for everything except the ASR. Form 3989 is only for the ASR.

Mistake 2: Using Incorrect PMR/PMC Number Format

What happens: CDER and CBER use different formats for PMR/PMC numbers. CDER uses XXXX-XX (e.g., 1234-10). CBER uses STN XXXXX/XXXX PMR/PMC # (e.g., STN 12345/5463 PMC 1). Using the wrong format can cause your submission to be mislinked in FDA tracking systems.

How to avoid it: Check your original approval letter or the PMR/PMC database to confirm the exact format used for your PMR/PMC.

Mistake 3: Failing to Include NCT Number for Clinical Trials

What happens: Clinical trials required under section 505(o)(3) must be registered on ClinicalTrials.gov. Your ASR must include documentation that the PMR is registered per Title VIII of FDAAA. Failure to include the NCT number can result in civil money penalties of up to $10,000 per violation, with additional penalties of up to $10,000 per day if uncorrected.

How to avoid it: Register your clinical trial on ClinicalTrials.gov before submitting the protocol. Include the NCT number in Section 9 of Form 3988.

Mistake 4: Not Using Cover Letter Headings Required for 505(o)(3) PMRs

What happens: When notifying FDA of missed or anticipated missed milestones for 505(o)(3) PMRs, specific cover letter headings are required. Without these headings, the FDA may not process your notification correctly, potentially affecting your “good cause” determination.

How to avoid it: Use the exact heading language from FDA guidance: “Notification of Failure to Meet a PMR Milestone(s) Required Under Section 505(o)” or “Notification of Anticipated Failure to Meet a PMR Milestone(s) Required Under Section 505(o).”

Mistake 5: Submitting Form 3988 with Cross-Reference Letters

What happens: When you submit a clinical protocol to your IND and send a cross-reference letter to the marketing application, the cross-reference letter should not include Form 3988. Including the form with cross-reference letters creates redundant submissions.

How to avoid it: Submit Form 3988 only with the actual protocol submission to the IND. The cross-reference letter stands alone.

Consequences of Non-Compliance

The FDA takes postmarketing study compliance seriously. The consequences of failing to meet your PMR or PMC obligations can be severe.

For Section 505(o)(3) PMRs

Under section 505(o)(3) of the FD&C Act, failing to comply with PMR requirements can result in:

Misbranding: Under section 502(z), your product is considered misbranded if you violate postmarketing study requirements. A misbranded product cannot be legally sold.

Civil Monetary Penalties: You may face penalties of up to $250,000 per violation, with additional penalties if the violation continues uncorrected.

Warning Letters: The FDA may issue a warning letter requiring you to correct violations and respond within 15 days. FDA issued its first 505(o)(3) warning letter to Merck in 2012 for failure to meet PMR milestones related to a pancreatitis safety study.

For PMCs and Non-505(o)(3) PMRs

While PMCs do not carry the same enforcement teeth as 505(o)(3) PMRs, consequences still exist:

Public Disclosure: The FDA publishes PMC status information in its searchable database. Delays are visible to healthcare professionals, patients, investors, and competitors.

Reputational Damage: A pattern of delayed or unfulfilled PMCs may affect your company’s relationship with FDA reviewers and impact future applications.

Accelerated Approval Withdrawals: For drugs granted accelerated approval, failure to conduct confirmatory trials with due diligence can result in expedited withdrawal of approval.

PMR/PMC Status Categories Explained

Understanding how the FDA classifies PMR/PMC status helps you track your compliance position. The FDA uses both “open” and “closed” status categories.

Open Status Categories

Closed Status Categories

Key point: A “delayed” status is based on the original schedule, not any revised schedule. However, if you fall behind in one phase but get back on track in the next, the delayed status no longer applies.

Do’s and Don’ts for Form 3988 Compliance

Do’s

✅ Do submit Form 3988 electronically via eCTD. Under section 745A(a), electronic submission is required for NDAs, ANDAs, BLAs, and commercial INDs.

✅ Do match the submission date on Form 3988 to your cover letter date. Inconsistent dates can create tracking issues.

✅ Do use the “Add Row” button if your submission covers more than three PMRs/PMCs. The form accommodates multiple requirements.

✅ Do continue annual reporting until you receive written fulfillment or release notification. Your obligations do not end when you submit a final report.

✅ Do register clinical trials on ClinicalTrials.gov and include NCT numbers. This is legally required for certain PMRs and helps avoid civil penalties.

Don’ts

❌ Don’t include Form 3988 with Annual Status Reports. Use Form 3989 for ASRs.

❌ Don’t submit a protocol to your IND and forget the cross-reference letter to the marketing application. The FDA needs both documents properly linked.

❌ Don’t assume the FDA considers your protocol “final” just because you marked it as such. FDA concurrence is required.

❌ Don’t ignore milestone deadlines without notifying FDA. For 505(o)(3) PMRs, this can trigger misbranding charges.

❌ Don’t use the wrong PMR/PMC number format. CDER and CBER formats differ.

Key Entities and Their Roles

Several FDA centers, regulations, and statutory provisions interact when dealing with Form 3988 and postmarketing requirements.

FDA Centers

CDER (Center for Drug Evaluation and Research): Reviews most NDAs and ANDAs. Manages the majority of drug-related PMRs and PMCs.

CBER (Center for Biologics Evaluation and Research): Reviews BLAs and manages PMRs/PMCs for biological products, vaccines, blood products, and some gene therapies.

Key Regulations

21 CFR 314.81(b)(2)(vii): Requires NDA and ANDA holders to submit annual status reports on PMRs and PMCs concerning clinical safety, efficacy, pharmacology, or nonclinical toxicology.

21 CFR 601.70: The parallel regulation for BLA holders, requiring the same annual reporting on PMRs and PMCs.

Key Statutes

Section 505(o)(3) of the FD&C Act: Authorizes FDA to require postmarketing studies or clinical trials to assess known serious risks, signals of serious risk, or potential for unexpected serious risk.

Section 505B of the FD&C Act (PREA): Requires pediatric studies for drugs and biologics under certain circumstances.

Section 506B of the FD&C Act: Establishes annual reporting requirements for postmarketing studies and clinical trials.

Section 502(z) of the FD&C Act: Defines postmarketing study violations as a basis for misbranding.

Pros and Cons of Using FDA Forms 3988 and 3989

While the FDA does not require use of Forms 3988 and 3989 (you can submit information in other formats), there are advantages and disadvantages to using these standardized forms.

Pros

✅ Automated Processing: The forms allow the FDA to process submissions automatically, reducing routing errors and delays.

✅ Standardized Format: Provides a consistent structure that FDA reviewers expect, improving the likelihood of correct interpretation.

✅ Electronic Signature Support: Both forms support electronic signatures, eliminating the need for wet signatures.

✅ Enhanced Database Accuracy: Information submitted via these forms feeds directly into FDA’s PMR/PMC tracking databases, ensuring your status is accurately recorded.

✅ Reduced Ambiguity: Predefined fields leave less room for error compared to free-form submissions.

Cons

❌ Learning Curve: Regulatory staff unfamiliar with the forms may initially find them time-consuming to complete correctly.

❌ Technology Requirements: Electronic submission requires eCTD publishing tools and access to FDA’s Electronic Submissions Gateway.

❌ Form Updates: FDA may revise the forms over time, requiring you to stay current with the latest versions.

❌ Rigid Structure: Some unique situations may not fit neatly into the predefined fields, requiring additional explanation in Field 11 or a cover letter.

❌ Duplicate Documentation: You must still submit other required forms (like Form 356h and Form 2252) alongside Forms 3988 and 3989.

FAQs

Is FDA Form 3988 mandatory?
No. Use of Form 3988 is optional, but the FDA strongly encourages it because the form enables automated processing and improves tracking accuracy.

Can I submit Form 3988 on paper?
No. If you choose to use Form 3988, you must submit it electronically via eCTD.

Does Form 3988 replace Form FDA 356h?
No. You must still submit Form 356h with your original and supplemental NDAs, ANDAs, and BLAs as applicable.

Should I use Form 3988 for my Annual Status Report?
No. Use Form 3989 for Annual Status Reports. Form 3988 is for all other PMR/PMC-related submissions.

What if my PMR involves multiple clinical trials?
Yes, you can include multiple PMRs or PMCs on a single Form 3988 by using the “Add Row” button in Section 9.

Do I need to include my NCT number on Form 3988?
Yes, if your PMR involves a clinical trial registered on ClinicalTrials.gov. Enter the NCT number in Section 9.

What happens if I miss a PMR milestone?
Yes, there are consequences. For 505(o)(3) PMRs, missing a milestone without good cause can result in misbranding charges and civil penalties up to $250,000.

Can I request release from a PMR I agreed to conduct?
Yes. Submit Form 3988 with “Request for Release of PMR/PMC” checked in Field 10 and provide justification explaining why the study is no longer feasible or useful.

How soon after FDA approval must I submit my first PMR/PMC-related document?
Yes, timelines vary. Draft protocols are typically due within months of approval. Check your approval letter for specific milestone dates.

What’s the difference between “fulfilled” and “released” status?
Yes, these are both closed statuses, but they differ. Fulfilled means you completed the study and FDA determined you met the terms. Released means FDA determined the study is no longer feasible or necessary.

Do PMCs carry the same penalties as PMRs?
No. PMCs are voluntary commitments. While you must report annually, PMCs do not carry misbranding or civil penalty consequences under section 505(o)(3). However, failure to conduct agreed-upon PMCs can affect your regulatory relationship.

Can the FDA withdraw approval if I don’t complete a confirmatory trial for accelerated approval?
Yes. Under FDORA (2022), the FDA has expedited procedures to withdraw accelerated approval if sponsors fail to conduct confirmatory trials with due diligence or if the trial fails to verify clinical benefit.